Serum annexin A2 levels were significantly higher in HCC patients compared with non-HCC controls and did not correlate with gender, age, tumor size, differentiation degree, BCLC staging, and AFP levels (144), with a better performance than AFP (AUROC 0.800 vs. 0.690) for distinguishing HCC from hepatitis and cirrhosis. Here, ANXA2 is linked to hepatocellular carcinoma.